Get the Stockscreener App
0.831
13.44%
-0.129
Pasithea Therapeutics Corp stock is traded at $0.831, with a volume of 2.00M.
It is down -13.44% in the last 24 hours and down -23.76% over the past month.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).
See More
Previous Close:
$0.96
Open:
$0.95
24h Volume:
2.00M
Relative Volume:
0.33
Market Cap:
$3.79M
Revenue:
-
Net Income/Loss:
$-16.28M
P/E Ratio:
-0.0597
EPS:
-13.91
Net Cash Flow:
$-13.75M
1W Performance:
-40.64%
1M Performance:
-23.76%
6M Performance:
-74.89%
1Y Performance:
-89.18%
1-Day Range:
$0.797
$0.9695
1-Week Range:
$0.797
$3.79
52-Week Range:
$0.797
$7.50
Pasithea Therapeutics Corp Stock (KTTA) Company Profile
Name
Pasithea Therapeutics Corp
Sector
Industry
Phone
(702) 514-4174
Address
1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH
Compare KTTA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KTTA
Pasithea Therapeutics Corp
|
0.831 | 3.79M | 0 | -16.28M | -13.75M | -13.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Pasithea Therapeutics Corp Stock (KTTA) Latest News
Pasithea Therapeutics Raises $6.3 Million in Stock Offering - TipRanks
Pasithea Therapeutics Closes $5 Million Public Offering to Advance Development of PAS-004 for Neurofibromatosis and Cancer Indications - Nasdaq
Pasithea Therapeutics Announces Closing of $5 Million Public Offering - GlobeNewswire
Pasithea Therapeutics 3.57M share Secondary priced at $1.40 - Yahoo Finance
Pasithea Therapeutics Stock Soars After Positive Data From Cancer Drug Trial: Retail’s Elated - Asianet Newsable
Pasithea Therapeutics Announces Pricing Of $5 Million Public Offering - marketscreener.com
Pasithea Therapeutics Prices $5 Million Public Offering - marketscreener.com
Pasithea Therapeutics announces interim data from Phase 1 trial of PAS-004 - TipRanks
Pasithea Therapeutics Announces Pricing of $5 Million Public Offering - The Manila Times
Pasithea Therapeutics (KTTA) Skyrockets: Stock Soars Over 115% in Morning Trade - apnakal
$5M Public Offering: Pasithea Therapeutics Advances MEK Inhibitor Drug for Rare Disease Treatment - Stock Titan
Pasithea Therapeutics Drug Shows Tumor Reduction In Pancreatic Cancer, Strong Early Trial Results - Benzinga
Pre-market Movers: KTTA, SXTC, GLMD, TCMD... - RTTNews
Pasithea reports promising data on cancer drug PAS-004 - Investing.com
Pasithea Therapeutics Reports Promising Phase 1 Trial Results for PAS-004, Demonstrating Up to 91% pERK Inhibition and Tumor Volume Reduction in Advanced Cancer Patients - Nasdaq
Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004 - GlobeNewswire
Phase 1 Trial Reveals 91% Target Success: New Cancer Drug Shows Promise in Pancreatic Cancer Patient - Stock Titan
Pasithea Therapeutics Files For Offering Up To 3.2 Mln Common Shares Together With Warrants, Says SEC Filing - marketscreener.com
Pasithea completes enrollment in cohort 6 of Phase 1 trial of PAS-004 - TipRanks
Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients - The Manila Times
Pasithea's Cancer Drug Trial Hits Key Milestone: Latest Results from Advanced Treatment Study - Stock Titan
Pasithea Therapeutics Announces Acceptance of Abstract for ASCO 2025 Presentation on PAS-004 Clinical Trial Data - Nasdaq
Pasithea Therapeutics to Present Updated Data from Ongoing - GlobeNewswire
New PAS-004 Cancer Trial Data Shows Clinical Activity and Safety Profile | KTTA Stock News - Stock Titan
Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting - The Manila Times
Pasithea Therapeutics Leads Healthcare Buzz Surge As Cancer Trial Clears Safety Hurdle, Moves To Next Dosing C - Asianet Newsable
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Pasithea Therapeutics Leads Healthcare Buzz Surge As Cancer Trial Clears Safety Hurdle, Moves To Next Dosing Cohort - MSN
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Pasithea Therapeutics progresses with cancer drug trial By Investing.com - Investing.com South Africa
Crude Oil Falls Over 4%; Keros Therapeutics Shares Jump - Benzinga
Pasithea Therapeutics Gets Positive Safety Committee Recommendation for Advanced Cancer Drug Phase 1 Trial - marketscreener.com
Dow Tumbles Over 800 Points; US Inflation Rate Falls In March - Benzinga
KTTA’s Unexpected Surge: Analysis of Recent Performance - timothysykes.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Pasithea Therapeutics progresses with cancer drug trial - Investing.com
Pasithea Therapeutics Announces Positive Safety Review Committee (Src) Recommendation From Its Ongoing Phase 1 Clinical Trial Of Pas-004 In Advanced Cancer - MarketScreener
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer - GlobeNewswire
Pasithea Therapeutics Corp. Announces Positive Safety Review Committee Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer - marketscreener.com
3 Reasons to Avoid HEES and 1 Stock to Buy Instead - The Globe and Mail
Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update - Yahoo Finance
U.S. Exosomes Market to Surge from $101 Million to $1,917.72 Million by 2034 | Towards Healthcare - Yahoo Finance
60 Degrees and Yale to progress tafenoquin for babesiosis - Yahoo Finance
European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility - Yahoo Finance
NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment - Yahoo Finance
If You Invested $10K In PotlatchDeltic Stock 10 Years Ago, How Much Would You Have Now? - Yahoo Finance
ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET - Yahoo Finance
Why Viking Holdings Ltd. (VIK) Surged On Tuesday? - Yahoo Finance
Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson's Disease - Yahoo Finance
SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML - Yahoo Finance
Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting at the Oncology Nursing Society (ONS) Congress for the FDA-Approved Gelclair Oral Mucositis Prescription Product - Yahoo Finance
Pasithea Therapeutics Corp Stock (KTTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):